News & Updates

Show Multimedia Only

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

17 Nov 2023 by

Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.

17 Nov 2023

Topical diclofenac prevents HFS in capecitabine-treated cancer patients

15 Nov 2023 by

Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.

15 Nov 2023

JAK inhibitor use tied to increased odds of acne

12 Nov 2023

Exposure to Janus kinase (JAK) inhibitors potentially carries an increased likelihood of developing acne, according to a study.

12 Nov 2023

Original New Drug Application Approvals by US FDA (16-31 October 2023)

08 Nov 2023

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

08 Nov 2023

What are the risk factors for severe actinic keratosis?

31 Oct 2023

Older age, lower skin phototype classifications, and a personal history of skin cancer may influence the severity of actinic keratosis (AK), while the use of calcium channel blockers (CCBs) is linked to more severe AK, as reported in a study.

31 Oct 2023

Nailfold capillary abnormalities predict PAO in palmoplantar pustulosis

27 Oct 2023

Abnormalities of nailfold capillary (NHC) appear predictive of pustulotic arthro-osteitis (PAO) in patients with palmoplantar pustulosis (PPP), while their degree indicators may predict disease severity, according to a prospective cohort study.

27 Oct 2023

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

27 Oct 2023

Use of ivarmacitinib 4- and 8-mg doses for 24 weeks eases hair loss and is generally tolerated in patients with moderate or severe alopecia areata (AA), a phase II study has shown.

27 Oct 2023

Histologic margin status predicts relapse in lentigo maligna melanoma

26 Oct 2023

Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.

26 Oct 2023

Brentuximab vedotin fares well for CTCL in real-world study

26 Oct 2023 by

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).

26 Oct 2023

How safe is long-term bimekizumab in plaque psoriasis patients?

24 Oct 2023 by

Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.

24 Oct 2023

News & Updates

Showing Dermatology articles

Showing

Specialty:

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

Topical diclofenac prevents HFS in capecitabine-treated cancer patients

JAK inhibitor use tied to increased odds of acne

Original New Drug Application Approvals by US FDA (16-31 October 2023)

What are the risk factors for severe actinic keratosis?

Nailfold capillary abnormalities predict PAO in palmoplantar pustulosis

Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata

Histologic margin status predicts relapse in lentigo maligna melanoma

Brentuximab vedotin fares well for CTCL in real-world study

How safe is long-term bimekizumab in plaque psoriasis patients?